GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » IDT Australia Ltd (ASX:IDT) » Definitions » ROE % Adjusted to Book Value

IDT Australia (ASX:IDT) ROE % Adjusted to Book Value : -14.66% (As of Dec. 2024)


View and export this data going back to 1991. Start your Free Trial

What is IDT Australia ROE % Adjusted to Book Value?

IDT Australia's ROE % for the quarter that ended in Dec. 2024 was -25.95%. IDT Australia's PB Ratio for the quarter that ended in Dec. 2024 was 1.77. IDT Australia's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -14.66%.


IDT Australia ROE % Adjusted to Book Value Historical Data

The historical data trend for IDT Australia's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDT Australia ROE % Adjusted to Book Value Chart

IDT Australia Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.70 2.92 -4.13 -40.54 -13.87

IDT Australia Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -57.25 -27.32 -19.59 -8.14 -14.66

Competitive Comparison of IDT Australia's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, IDT Australia's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDT Australia's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, IDT Australia's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where IDT Australia's ROE % Adjusted to Book Value falls into.


;
;

IDT Australia ROE % Adjusted to Book Value Calculation

IDT Australia's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-22.75% / 1.64
=-13.87%

IDT Australia's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-25.95% / 1.77
=-14.66%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IDT Australia ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of IDT Australia's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


IDT Australia Business Description

Traded in Other Exchanges
N/A
Address
45 Wadhurst Drive, Boronia, Melbourne, VIC, AUS, 3155
IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services.